Roivant’s Growth and Clinical Progress in Q1 2024
Roivant reports strong clinical progress, with significant Phase 3 study completions, revenue growth, and financial strength.
- Latest
- Trending
Roivant reports strong clinical progress, with significant Phase 3 study completions, revenue growth, and financial strength.
Wolfe Research initiates coverage on Roivant Sciences, assigning an outperform rating with a price target of $17.00. Their analysis highlights ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.